Sabra Healthcare REIT Inc (SBRA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sabra Healthcare REIT Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 21.20 $ — 77% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 7.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 13
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.67 | 0.66 – 0.67 | 898 | – | 2 |
| 12/31/2027 | 0.76 | 0.71 – 0.80 | 988 | 14.3% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.38 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.19 | 164.90 | 182 | 11.60 | 25.60 | 80 | 80 |
| 2025: Q1 | 0.17 | 49.10 | 184 | 10.10 | 22.00 | 80 | 80 |
| 2025: Q2 | 0.27 | 165.20 | 189 | 7.40 | 34.70 | 81 | 81 |
| 2025: Q3 | 0.09 | -26.40 | 190 | 6.80 | 11.90 | 100 | 100 |
| 2025: Q4 | 0.11 | -44.70 | 212 | 16.20 | 12.80 | 87 | 87 |
| 2026: Q1 | 0.16 | -4.80 | 222 | 20.80 | 18.40 | 98 | 98 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 261 | 161 | 70 | 1.07 | 177 | 1,016 | 2,266 |
| 2017 | 406 | 224 | 158 | 1.50 | 133 | 3,433 | 7,032 |
| 2018 | 623 | 307 | 279 | 1.56 | 359 | 3,250 | 6,665 |
| 2019 | 668 | 528 | 69 | 0.37 | 372 | 3,488 | 6,069 |
| 2020 | 599 | 241 | 138 | 0.67 | 355 | 3,409 | 5,986 |
| 2021 | 570 | 211 | -113 | -0.52 | 356 | 3,380 | 5,967 |
| 2022 | 625 | 235 | -78 | -0.34 | 316 | 3,056 | 5,748 |
| 2023 | 648 | 222 | 14 | 0.06 | 301 | 2,803 | 5,386 |
| 2024 | 703 | 257 | 127 | 0.54 | 311 | 2,741 | 5,304 |
| 2025 | 775 | 264 | 156 | 0.64 | 349 | 2,822 | 5,493 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Sabra Health Care REIT, Inc. ist ein selbstverwalteter Immobilien-Investmenttrust (REIT), der über seine Tochtergesellschaften Immobilien für die Gesundheitsbranche in den USA und Kanada besitzt und in solche investiert.
| Employees | 58 |
|---|---|
| Headquarters | Tustin, CA |
| Address | 1781 Flight Way, 92782-0539 Tustin, United States |
| Phone | 888 393 8248 |
| Website | sabrahealth.com |
| IPO Date | 2. Apr 2002 |
| ISIN | US78573L1061 |
| Stock Split | 1:3 on 11/16/2010 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Richard K. Matros | Chairman, President & CEO | 1954 |
| Michael Lourenco Costa CPA | Executive VP, CFO & Treasurer | 1979 |
| Darrin L. Smith | Chief Investment Officer, Secretary & Executive VP | 1969 |
| Jessica Flores | Executive VP & Chief Accounting Officer | 1983 |
| Peter W. Nyland | Executive Vice President of Strategic Initiatives | – |
| Lukas Michael Hartwich C.F.A. | Executive Vice President of Finance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.